4P-PHARMA
14.3.2024 11:36:29 CET | Business Wire | Press release
4P-Pharma, a clinical-stage biotech based in Lille dedicated to developing curative therapies for serious untreated diseases, is thrilled to announce the appointment of Jérôme Vailland as Chief Financial Officer (CFO) for 4P-Pharma and its subsidiaries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314228336/en/
Jérôme Vailland 4P-Pharma Chief Financial Officer (Photo: Business Wire)
Jérôme Vailland built a solid career with significant contributions at Ernst & Young (EY), where he worked for 10+ years. He gained extensive experience in financial audit, company structuring, transactions, and IPOs across European and American markets, mainly in life sciences. Over the years, he held several positions up to Senior Manager, managing and advising numerous clients while assuming broader technical and managerial responsibilities.
Following his strong experience at EY, Jérôme joined Horama, now Coave Therapeutics, in 2016, serving as Chief Financial Officer. He successfully raised funds for the company by leveraging his strategic and leadership skills. In 2020, he became Chief Financial Officer of a biotechnology company listed on the Euronext Paris regulated market, focusing on developing tools and services for genome modification analysis and control.
These positions underscore his deep understanding of the financial challenges faced by public and private biotech companies and the practical solutions that must be implemented to deliver efficient results.
By joining the company's executive team, Jérôme Vailland will contribute to supporting the company's growth, especially through effective and transparent financial management. Jérôme Vailland's recognized finance skills and excellent understanding of organization structuring will be an asset for 4P-Pharma.
Revital Rattenbach, CEO of 4P-Pharma, stated: "As 4P-Pharma celebrates a decade of innovation, we welcome Jérôme Vailland as our new CFO. His experience and skills in finance are essential for our growth and transition into a successful organization. With Jérôme’s leadership, we look forward to a future of stability and continued success, reassuring our investors and partners in the pharmaceutical community of our commitment to excellence and sustainability."
Regarding his appointment as Chief Financial Officer, Jérôme Vailland said, "I am thrilled to join 4P-Pharma at a decisive moment, especially with two drug candidates prepared to enter Phase II clinical trials. I look forward to working with the team and exploring all scientific and financial options to advance the mission of 4P-Pharma and its subsidiaries."
About 4P-Pharma
Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class therapies to patients rapidly. 4P-Pharma leverages drug candidates with reduced development timelines, thanks partly to regulatory opportunities ("emergency use" or conditional marketing authorization) with strong intellectual property. The company is based in Lille and Paris and has over 20 employees.
Website: https://4p-pharma.com/en
LinkedIn: https://www.linkedin.com/company/4p-pharma
X: https://twitter.com/4P_Pharma
The only legally binding version of the 4P-Pharma press release is the one in its original language. Translations should be compared to the source text, which takes precedence. The press release text resulting from a translation should not be considered official.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314228336/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenAI and Yubico Partner to Bring Custom Phishing-Resistant YubiKeys to OpenAI Users30.4.2026 19:13:00 CEST | Press release
New strategic, long-term partnership with OpenAI delivers the gold standard of hardware-backed passkeys to the AI ecosystem Yubico (NASDAQ STOCKHOLM: YUBICO), the pioneer of phishing-resistant authentication and creator of the YubiKey, the gold standard of security keys, today announced an industry-first collaboration with OpenAI, the creator of ChatGPT. Beginning today, people can purchase a new 2-pack set of custom YubiKeys as part of OpenAI’s Advanced Account Security program – enabling them to secure their ChatGPT accounts with security keys, containing the strongest hardware-backed passkeys. Specifically designed for security-conscious users who are at increased risk of targeted digital attacks, the set includes a YubiKey C NFC for tap-to-authenticate on mobile, and a low profile YubiKey C Nano that stays in a port for everyday laptop use – both packed with modern authentication features for the highest level of protection. With OpenAI already using YubiKeys internally to protect
rhode Continues Its Global Retail Expansion Into Sephora Europe30.4.2026 18:00:00 CEST | Press release
This expansion into Sephora Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand rhode, the beauty brand founded by Hailey Rhode Bieber, will be available at Sephora online and in most stores across Europe beginning this September, following its 2025 rollout with Sephora in the U.S., Canada, and the U.K. This expansion into Sephora Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430569580/en/ rhode continues its global retail expansion into Sephora Europe. rhode’s collection of high-performance, skin-focused products saw strong performance in Sephora U.S. and Canada as the biggest brand launch in the retailer’s history in North America. When launched in November 2025 in the U.K., rhode was also the largest brand launch in Sephora U.K.’s history. “I’m so excited
ABS Acquires RMC Global to Strengthen Cyber, Risk and Resilience Capabilities30.4.2026 17:46:00 CEST | Press release
Acquisition to Deliver Stronger, More Integrated Solutions for Clients ABS, through its affiliate ABSG Consulting Inc. (ABS Consulting), has today announced the acquisition of RMC Global (RMC), a leading provider of industrial cybersecurity, risk management and resiliency solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430164690/en/ (L to R): Vince Kuchar, President, RMC Global, and David Wechsler, President and CEO, ABS Group The acquisition strengthens ABS Consulting’s capabilities and market position, bringing together two organizations with complementary expertise, shared values and a common mission. Combining RMC’s capabilities with ABS Consulting’s scale, technical depth and global resources, unlocks more integrated solutions for clients operating in increasingly complex risk environments. ABS Chairman and CEO John McDonald said: “Clients are facing increasing operational risk, cyber threats, and regulator
Brightfin Unveils AI-Native Platform for IT Financial Management30.4.2026 17:00:00 CEST | Press release
Brightfin clients drive their businesses forward with the first AI Native Cost Optimization Platform Brightfin, the only ITFM and Technology Expense Management solution built natively on ServiceNow, today announced an AI-Native architecture that fundamentally improves how organizations manage IT spend. Rather than bolting AI onto legacy systems, Brightfin has engineered intelligence from the ground up - starting with the data, building contextual awareness on top of it, and delivering AI agents that speak the language of IT finance. Brightfin’s unified budget-to-billing data model creates a stable, governed foundation that connects contracts, invoices, inventory, and budgets into a single source of truth - something no external ITFM tool or native platform module can replicate. This is a structured financial backbone purpose-built for enterprise IT spend, and it’s what makes everything above it possible. A context-aware, AI-Native, intelligence layer understands relationships across th
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 202430.4.2026 15:22:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SINOVAC’s investor relations website at https://www.sinovac.com/en-us/Investors and on the SEC’s website at www.sec.gov. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases. The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, et
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom